Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors

Caroline E. Porter; Amanda Rosewell Shaw; Youngrock Jung; Tiffany Yip; Patricia D. Castro; Vlad C. Sandulache; Andrew Sikora; Stephen Gottschalk; Michael M. Ittman; Malcolm K. Brenner; Masataka Suzuki

doi:10.1016/j.ymthe.2020.02.016

Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors

Caroline E. Porter, Amanda Rosewell Shaw, Youngrock Jung, Tiffany Yip, Patricia D. Castro, Vlad C. Sandulache, Andrew Sikora, Stephen Gottschalk, Michael M. Ittman, Malcolm K. Brenner, Masataka Suzuki

Research output: Contribution to journal › Article › peer-review

89 Scopus citations

Abstract

To enable HER2.CAR T cells to target two tumor antigens through both CAR and native TCR, Porter et al. developed a binary oncolytic-helper adenovirus expressing an engager molecule (BiTE), IL-12, and PD-L1 antibody. This combination therapy significantly improved tumor control and survival in models of HER2-positive and HER-negative cancer.

Original language	English (US)
Pages (from-to)	1251-1262
Number of pages	12
Journal	Molecular Therapy
Volume	28
Issue number	5
DOIs	https://doi.org/10.1016/j.ymthe.2020.02.016
State	Published - May 6 2020
Externally published	Yes

Keywords

oncolytic viro-immunotherapy, CAR T cell, BiTE molecule, cytokine, checkpoint inhibitor, CD44 variant 6

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Genetics
Pharmacology
Drug Discovery

Access to Document

10.1016/j.ymthe.2020.02.016

Cite this

Porter, C. E., Rosewell Shaw, A., Jung, Y., Yip, T., Castro, P. D., Sandulache, V. C., Sikora, A., Gottschalk, S., Ittman, M. M., Brenner, M. K., & Suzuki, M. (2020). Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Molecular Therapy, 28(5), 1251-1262. https://doi.org/10.1016/j.ymthe.2020.02.016

Porter, CE, Rosewell Shaw, A, Jung, Y, Yip, T, Castro, PD, Sandulache, VC, Sikora, A, Gottschalk, S, Ittman, MM, Brenner, MK & Suzuki, M 2020, 'Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors', Molecular Therapy, vol. 28, no. 5, pp. 1251-1262. https://doi.org/10.1016/j.ymthe.2020.02.016

@article{d3b665d9d56a42bc93660d629d55176c,

title = "Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors",

abstract = "To enable HER2.CAR T cells to target two tumor antigens through both CAR and native TCR, Porter et al. developed a binary oncolytic-helper adenovirus expressing an engager molecule (BiTE), IL-12, and PD-L1 antibody. This combination therapy significantly improved tumor control and survival in models of HER2-positive and HER-negative cancer.",

keywords = "oncolytic viro-immunotherapy, CAR T cell, BiTE molecule, cytokine, checkpoint inhibitor, CD44 variant 6",

author = "Porter, {Caroline E.} and {Rosewell Shaw}, Amanda and Youngrock Jung and Tiffany Yip and Castro, {Patricia D.} and Sandulache, {Vlad C.} and Andrew Sikora and Stephen Gottschalk and Ittman, {Michael M.} and Brenner, {Malcolm K.} and Masataka Suzuki",

note = "Publisher Copyright: {\textcopyright} 2020 The American Society of Gene and Cell Therapy",

year = "2020",

month = may,

day = "6",

doi = "10.1016/j.ymthe.2020.02.016",

language = "English (US)",

volume = "28",

pages = "1251--1262",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors

AU - Porter, Caroline E.

AU - Rosewell Shaw, Amanda

AU - Jung, Youngrock

AU - Yip, Tiffany

AU - Castro, Patricia D.

AU - Sandulache, Vlad C.

AU - Sikora, Andrew

AU - Gottschalk, Stephen

AU - Ittman, Michael M.

AU - Brenner, Malcolm K.

AU - Suzuki, Masataka

PY - 2020/5/6

Y1 - 2020/5/6

N2 - To enable HER2.CAR T cells to target two tumor antigens through both CAR and native TCR, Porter et al. developed a binary oncolytic-helper adenovirus expressing an engager molecule (BiTE), IL-12, and PD-L1 antibody. This combination therapy significantly improved tumor control and survival in models of HER2-positive and HER-negative cancer.

AB - To enable HER2.CAR T cells to target two tumor antigens through both CAR and native TCR, Porter et al. developed a binary oncolytic-helper adenovirus expressing an engager molecule (BiTE), IL-12, and PD-L1 antibody. This combination therapy significantly improved tumor control and survival in models of HER2-positive and HER-negative cancer.

KW - oncolytic viro-immunotherapy, CAR T cell, BiTE molecule, cytokine, checkpoint inhibitor, CD44 variant 6

UR - http://www.scopus.com/inward/record.url?scp=85081221625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081221625&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2020.02.016

DO - 10.1016/j.ymthe.2020.02.016

M3 - Article

C2 - 32145203

AN - SCOPUS:85081221625

SN - 1525-0016

VL - 28

SP - 1251

EP - 1262

JO - Molecular Therapy

JF - Molecular Therapy

IS - 5

ER -

Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this